Expression of galectin-3 in cervical cancer and its clinical significance

Tumor

Volumn 31, Issue 2, 2011, Pages 148-153

  Zhou, Yu Qi ^a,b   Zhou, Xue Ke ^a,b   Kong, Yun Yi ^a,b   Song, Chun Yan ^a,b   Wu, Xiao Hua ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Galectin 3; Microchip analytical procedures; Neoplasm metastasis; Prognosis; Uterine cervical neoplasms

Indexed keywords

GALECTIN 3;

ARTICLE; CANCER INVASION; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MUSCLE METASTASIS; OVERALL SURVIVAL; PELVIS LYMPH NODE; PREOPERATIVE RADIOTHERAPY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RISK FACTOR; TISSUE MICROARRAY; TREATMENT OUTCOME; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

EID: 79952539809     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2011.02.012     Document Type: Article

References (14)

1. CANESIN G, GONZALEZ-PERAMATO P, PALOU J, et al. Galectin-3 expression is associated with bladder cancer progression and clinical outcome[J]. Tumour Biol, 2010, 31(4): 277-285.
2. SAKAKI M, FUKUMORI T, FUKAWA T, et al. Clinical significance of Galectin-3 in clear cell renal cell carcinoma[J]. J Med Invest, 2010, 57(1/2): 152-157.
3. ENDO K, KOHNOE S, TSUJITA E, et al. Galectin-3 expression is a potent prognostic marker in colorectal cancer[J]. Anticancer Res, 2005, 25(4): 3117-3121.
4. MIYAZAKI J, HOKARI R, KATO S, et al. Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes[J]. Oncol Rep, 2002, 9(6): 1307-1312.
5. MERSEBURGER A S, KRAMER M W, HENNENL OTTER J, et al. Invol vement of decreased galectin-3 expression in the pathogenesis and progression of prostate cancer[J]. Prostate, 2008, 68(1): 72-77.
6. MATHIEU A, SAAL I, VUCKOVIC A, et al. Nuclear galectin - 3 expression is an independent predictive factor of recurrence for adenocarcinoma and squamous cell carcinoma of the lung[J]. Mod Pathol, 2005, 18(9): 1264-1271.
7. LEE J W, SONG S Y, CHOI J J, et al. Decreased galectin-3 expression during the progression of cervical neoplasia[J]. J Cancer Res Clin Oncol, 2006, 132(4): 241-247.
8. HSU C G, LIN L Y, KO J L, et al. High expression of human nonmetastatic clone 23 type 1 in cancer of uterine cervix and its association with poor cell differentiation and worse overall survival[J]. J Surg Oncol, 2008, 98(6): 448-456.
9. YANG R Y, HSU D K, LIU F T. Expression of galectin-3 modulates T-cell growth and apoptosis[J]. Proc Natl Acad Sci U S A, 1996, 93(13): 6737-6742.
10. NANGIA-MAKKER P, HONJO Y, SARVIS R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis[J]. Am J Pathol, 2000, 156(3): 899-909.
11. SHEKHAR M P, NANGIA-MAKKER P, TAIT L, et al. Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions[J]. Am J Pathol, 2004, 165(6): 1931-1941.
12. MATARRESE P, FUSCO O, TINARI N, et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties[J]. Int J Cancer, 2000, 85(4): 545-554.
13. FUKUMORI T, KANAYAMA H O, RAZ A. The role of galectin-3 in cancer drug resistance[J]. Drug Resist Updat, 2007, 10(3): 101-108.